REVESTIVE, also known by its generic name teduglutide, is a medication primarily used in the treatment of short bowel syndrome (SBS) in adults. Short bowel syndrome is a condition that typically arises when a significant portion of the small intestine has been removed or is not functioning properly, leading to difficulties in nutrient and fluid absorption. REVESTIVE works by mimicking the effects of naturally occurring glucagon-like peptide-2 (GLP-2), which helps to improve intestinal absorption by increasing the surface area of the remaining intestine. This effect is achieved through the promotion of intestinal growth and enhanced blood flow, potentially reducing the dependency on parenteral support (intravenous nutrition and fluids) for individuals with SBS. Administered through subcutaneous injection, REVESTIVE represents a significant advancement in the management of this challenging condition, offering hope for improved quality of life for affected patients.